Key Takeaways
- RDi USA Inc. debuts at ADLM 2026, delivering an end‑to‑end U.S. diagnostic pathway solution.
- The company leverages fully automated kit assembly, AI‑driven quality control, and domestic manufacturing to eliminate manual errors.
- Over 130 million kits and one billion patient records have already proven the model in the U.K. and global markets.
- RDi USA targets population screening, pathology, pharmacy testing, employer health programs, and direct‑to‑consumer services.
- Visitors can explore the solution at Booth 4454; meetings can be arranged via www.thisisrdi.com or the provided contact.
Company Launch Introduces U.S. Operations
RDi, a global specialist in diagnostics and healthcare infrastructure, has announced the creation of RDi USA Inc., a new subsidiary dedicated to scaling automated diagnostic kitting, fulfillment, and self‑sampling within the United States. The launch will be highlighted at the ADLM 2026 Annual Scientific Meeting & Clinical Lab Expo in Anaheim, where the team will showcase its capabilities at Booth 4454 from July 28 to 30. This move marks the company’s first dedicated U.S. entity and reflects a strategic shift toward serving American laboratories, manufacturers, and healthcare providers with a locally based operation.
Massive Proven Capacity Powers the Expansion
The subsidiary enters the market armed with a track record of success: more than 130 million self‑collection kits have been delivered worldwide, 163 distinct kit designs are registered, and over one billion patient data records have been processed across the RDi Group. Its high‑speed production lines can manufacture hundreds of thousands of kits daily, with robots handling assembly, inspection, and camera‑based quality validation. By removing human hands from the process, RDi eliminates the most common source of error in diagnostic kits, enabling screening programs to increase volume without sacrificing quality.
Domestic Manufacturing and Fulfillment Take Shape
RDi USA is establishing U.S.‑based manufacturing and fulfillment facilities that will give American customers direct access to the same automation, rigorous quality systems, and large‑scale expertise that have powered the company’s operations abroad. This localized infrastructure is intended to reduce lead times, improve supply chain resilience, and meet the growing expectation for rapid, reliable diagnostic services within the United States.
Integrated Pathway Platform Enhances Patient Experience
Central to RDi’s offering is the +CURA pathway platform, a digital ecosystem that guides patients from test ordering through kit activation, sample collection, return shipping, laboratory processing, and results delivery. The platform enables partners to maintain their own brand, clinical protocols, and laboratory relationships while benefitting from standardized, end‑to‑end connectivity. Features include custom kit design, automated assembly, direct‑to‑patient fulfillment, reverse‑logistics, laboratory integration, and real‑time pathway visibility, all supported by secure data handling and onward‑care recommendations.
Broad Market Focus Across Multiple Segments
RDi USA’s capabilities span a wide spectrum of diagnostic needs, including population‑based screening, pathology testing, clinical‑trial sampling, retail and pharmacy testing, occupational health programs, insurance‑driven health initiatives, wellness and genetics services, and direct‑to‑consumer offerings. By providing a unified infrastructure, the company aims to simplify complex testing pathways for each of these segments, allowing partners to scale their programs without the friction of fragmented suppliers or manual processes.
Leadership Perspectives Emphasize Seamless Integration
David Cahill, Group Chief Executive Officer of RDi, highlighted that an excellent diagnostic test achieves its full value only when every component of the pathway functions cohesively. He explained that RDi USA removes the “friction” of disconnected suppliers and limited visibility, offering an integrated operating model that couples automated manufacturing, fulfillment, logistics, digital technology, and laboratory integration into a single dependable pathway. Cahill noted that the launch coincides with a pivotal industry moment—ADLM 2026—where laboratory leaders converge to shape the future of diagnostics, especially as testing shifts toward home, workplace, and community settings.
Strategic Vision for U.S. Market Penetration
Chris Tagg, Chief Strategy Officer, described the U.S. launch as the next logical step in RDi’s evolution. After years of building automation, processes, and technology for high‑volume diagnostics, the company is now tailoring its operations to the specific demands of the American market. Tagg emphasized that the goal is to bring the same proven, scalable solution that has supported national screening programs in the U.K. and other regions to U.S. customers, ensuring they can expand testing capabilities safely and efficiently at a domestic scale.
Opportunity for Partners at ADLM 2026
Attendees of ADLM 2026 will have the chance to meet the RDi USA leadership team, view live demonstrations of the automated kitting and pathway platform, and discuss collaboration opportunities. The booth at the Anaheim Convention Center will serve as a hub for dialogue on how laboratories and healthcare brands can leverage RDi’s white‑label infrastructure to enhance patient engagement, streamline logistics, and gain real‑time insights into test workflow performance.
Contact Information and Further Engagement
Parties interested in learning more or arranging meetings can visit www.thisisrdi.com or reach out via the provided contact email. Media inquiries may be directed to Nicola O’Shaughnessy, Marketing & PR Manager for RDi and RDi USA Inc., reachable at the same email address or by phone at +1 (980) 470‑4765. Additional details about the company’s mission—“Better healthcare, made possible”—and its global heritage are available on the corporate website.
Looking Ahead to a Connected Diagnostic Future
RDi USA’s entry into the United States represents a transformational step toward eliminating the bottlenecks that have historically limited the reach and reliability of diagnostic testing. By combining automated, error‑free kit production with a fully integrated digital pathway, the company aims to empower laboratories, manufacturers, and health systems to deliver tests wherever patients need them—whether at home, in a pharmacy, or within a community setting. The launch at ADLM 2026 sets the stage for a new era of scalable, high‑quality diagnostics that can adapt to the evolving needs of the U.S. healthcare landscape.